Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Biologics License Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
FDA Accepts LEQEMBI® IQLIKTM Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
FDA Accepts LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy
Biologics License Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease Accepted in China
